NF-κB as a potential molecular target for cancer therapy

Authors

  • Chae Hyeong Lee,

    1. Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea
    Search for more papers by this author
  • Yong-Tark Jeon,

    1. Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea
    Search for more papers by this author
  • Su-Hyeong Kim,

    1. Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Korea
    Search for more papers by this author
  • Yong-Sang Song

    Corresponding author
    1. Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea
    • Yong-Sang Song, Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, 28 Yeongeon-dong, Jongno-gu, Seoul, 110-744, Korea. Tel.: +82 2 2072 2822; Fax: +82 2 762 3599
    Search for more papers by this author

Abstract

Nuclear factor κB (NF-κB), a transcription factor, plays an important role in carcinogenesis as well as in the regulation of immune and inflammatory responses. NF-κB induces the expression of diverse target genes that promote cell proliferation, regulate apoptosis, facilitate angiogenesis and stimulate invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NF-κB activation which mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NF-κB activation and its signaling pathway offers a potential cancer therapy strategy. In addition, recent studies have shown that NF-κB can also play a tumor suppressor role in certain settings. In this review, we focus on the role of NF-κB in carcinogenesis and the therapeutic potential of targeting NF-κB in cancer therapy.

Ancillary